Haematologic Technologies (HTI) is the leading provider of coagulation reagents for research and diagnostic applications, as well as analytical services to support the research, development and commercialization of large molecule biotherapeutics. The Company’s services include highly advanced assay development and GMP testing in the areas of immunoassays, thrombin generation assays, assessment of hemostatic risk, anti-drug antibody testing (immunogenicity), host cell protein mitigation, and stability and release testing of biologic therapeutics in FDA-inspected GMP facilities.